Literature DB >> 34063785

Pneumococcal Vaccination in Immunocompromised Hosts: An Update.

Claire Froneman1, Peter Kelleher1,2, Ricardo J José1,3.   

Abstract

Infections with the pathogen, Streptococcus pneumoniae, are a common cause of morbidity and mortality worldwide. It particularly affects those at the extremes of age and immunocompromised individuals. Preventing pneumococcal disease is paramount in at risk individuals, and pneumococcal vaccination should be offered. Here, we discuss the role of pneumococcal vaccination in specific groups of immunocompromised hosts.

Entities:  

Keywords:  PCV13; PPV23; immunocompromised; pneumococcus; pneumonia; respiratory infection; streptococcus pneumoniae; vaccination

Year:  2021        PMID： 34063785     DOI： 10.3390/vaccines9060536

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN： 2076-393X


  80 in total

1.  The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents.

Authors:  S C Redd; G W Rutherford; M A Sande; A R Lifson; W K Hadley; R R Facklam; J S Spika
Journal:  J Infect Dis       Date:  1990-11       Impact factor: 5.226

2.  Pneumococcal vaccination and risk of myocardial infarction.

Authors:  François Lamontagne; Marie-Pierre Garant; Jean-Christophe Carvalho; Luc Lanthier; Marek Smieja; Danielle Pilon
Journal:  CMAJ       Date:  2008-10-07       Impact factor: 8.262

Review 3.  Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7).

Authors:  Malgorzata Mikulska; Simone Cesaro; Hugues de Lavallade; Roberta Di Blasi; Sigrun Einarsdottir; Giuseppe Gallo; Christina Rieger; Dan Engelhard; Thomas Lehrnbecher; Per Ljungman; Catherine Cordonnier
Journal:  Lancet Infect Dis       Date:  2019-02-08       Impact factor: 25.071

4.  The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis.

Authors:  Mariëlle van Aalst; Annefleur C Langedijk; René Spijker; Godelieve J de Bree; Martin P Grobusch; Abraham Goorhuis
Journal:  Vaccine       Date:  2018-08-16       Impact factor: 3.641

5.  Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults.

Authors:  Karlis Pauksens; Anna C Nilsson; Magalie Caubet; Thierry G Pascal; Pascale Van Belle; Jan T Poolman; Pierre G Vandepapelière; Vincent Verlant; Peter E Vink
Journal:  Clin Vaccine Immunol       Date:  2014-03-05

Review 6.  Secondary immunodeficiencies, including HIV infection.

Authors:  Javier Chinen; William T Shearer
Journal:  J Allergy Clin Immunol       Date:  2009-12-29       Impact factor: 10.793

7.  Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.

Authors:  Steven M Horwitz; Robert S Negrin; Karl G Blume; Sheila Breslin; Monic J Stuart; Keith E Stockerl-Goldstein; Laura J Johnston; Ruby M Wong; Judith A Shizuru; Sandra J Horning
Journal:  Blood       Date:  2003-08-07       Impact factor: 22.113

8.  Pneumococcal vaccination rates in immunocompromised patients-A cohort study based on claims data from more than 200,000 patients in Germany.

Authors:  Niklas Schmedt; Julia Schiffner-Rohe; Ralf Sprenger; Jochen Walker; Christof von Eiff; Dennis Häckl
Journal:  PLoS One       Date:  2019-08-08       Impact factor: 3.240

Review 9.  Multifaceted Role of Pneumolysin in the Pathogenesis of Myocardial Injury in Community-Acquired Pneumonia.

Authors:  Ronald Anderson; Jan G Nel; Charles Feldman
Journal:  Int J Mol Sci       Date:  2018-04-11       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.